CSL Ltd.
-
FDA Green Lights CSL Behring’s Privigen for New Use
King of Prussia’s CSL Behring has received more positive news for its autoimmune and inflammatory disease disorder drug Privigen, as…
-
CEO of King of Prussia’s CSL Ltd. Discusses Impact of Gene Therapy
Paul Perreault, the 59-year-old chief executive officer and managing director of CSL Ltd., recently discussed with the Philadelphia Inquirer the…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
